SEC Company Response from AGENUS INC (AGEN) (CIK 0001098972) (AGEN) — Dec 12, 2017
AGENUS INC (AGEN) (CIK 0001098972)
Date: Dec. 12, 2017 · CIK: 0001098972 · Accession: 0001193125-17-367563
AI Filing Summary & Sentiment
File numbers found in text: 333-221465
Referenced dates: December 1, 2017
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 12, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Mary Beth Breslin Dorrie Yale Re: Agenus Inc. Registration Statement on Form S-3, filed November 9, 2017 File No. 333-221465 Ladies and Gentlemen: On behalf of Agenus Inc. (the “Company”), we submit via EDGAR this letter in response to the written comments of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission, dated December 1, 2017 (the “Comment Letter”), with regard to the Company’s above-referenced Registration Statement on Form S-3 (the “Registration Statement”). For the convenience of the Staff’s review, we have set forth the comment contained in the Comment Letter in italics followed by the response of the Company. General 1. We note that there is an outstanding comment on your 10-K for the fiscal year ended December 31, 2016 filed March 16, 2017, and on your Form 10-Q for the quarterly period ended September 30, 2017 filed on November 7, 2017. Please be advised that we will not be in a position to declare your registration statement effective until all comments on your Exchange Act filings are resolved. Response: The Company acknowledges the Staff’s comment that the Staff will not be in a position to declare the Company’s Registration Statement effective until all comments concerning the Company’s Exchange Act filings are resolved. We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions or comments about this letter or need any further information, please call the undersigned at (617) 951-7663. Very truly yours, /s/ Zachary R. Blume Zachary R. Blume cc: Evan Kearns (Agenus Inc.)